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Abstract
Skull base chordomas are challenging tumors due to their deep surgical location and resistance to conventional
radiotherapy. Chemotherapy plays a marginal role in the treatment of chordoma resulting from lack of preclinical
models due to the difficulty in establishing tumor cell lines and valuable in vivomodels. Here, we established a cell
line from a recurrent clival chordoma. Cells were cultured for more than 30 passages and the expression of the
chordoma cell marker brachyury was monitored using both immunohistochemistry and Western blot. Sensitivity of
chordoma cells to the inhibition of specific signaling pathways was assessed through testing of a commercially
available small molecule kinase inhibitor library. In vivo tumorigenicity was evaluated by grafting chordoma cells
onto immunocompromised mice and established tumor xenografts were treated with rapamycin. Rapamycin was
administered to the donor patient and its efficacy was assessed on follow-up neuroimaging. Chordoma cells main-
tained brachyury expression at late passages and generated xenografts closely mimicking the histology and phe-
notype of the parental tumor. Rapamycin was identified as an inhibitor of chordoma cell proliferation. Molecular
analyses on tumor cells showed activation of the mammalian target of rapamycin signaling pathway and mutation
of KRAS gene. Rapamycin was also effective in reducing the growth of chordoma xenografts. On the basis of these
results, our patient received rapamycin therapy with about six-fold reduction of the tumor growth rate upon 10-month
follow-up neuroimaging. This is the first case of chordoma in whom chemotherapy was tailored on the basis of the
sensitivity of patient-derived tumor cells.
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Introduction
Chordomas of the skull base are biologically aggressive tumors due to
their propensity to infiltrate the bone and dura mater. Current treat-
ment consists of extensive surgical resection followed by high-dose
radiation therapy. Even after appropriate treatment, however, skull
base chordomas recur by 29 to 43 months after initial surgery with
5-year progression-free survival ranging from 23% to 65% and median
overall survival of 6 years [1–7]. Chemotherapy plays only a marginal
role in the treatment of chordomas and this is largely related to the
lack of preclinical data due to the difficulty in establishing tumor cell
lines and relevant in vivo models. In a previous study, we were able
to derive long-term cell cultures from skull base chordomas showing
telomerase enzyme activity [8]. More recently, Siu et al. established
the first primary tumor xenograft model from a chordoma of the clivus
that had recurred following radiotherapy [9]. A few cell lines have been
isolated from sacral and extra-axial chordomas [10–16], three of which
were demonstrated to be tumorigenic after being grafted in immuno-
compromised mice [14–16]. Further studies on sacral chordoma cells
have shown activation of the phosphoinositide 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway and intrinsic
stem-like properties, including potential toward osteogenic differentia-
tion [17,18]. Here, we have established a novel cell line from a patient
suffering from a recurrent chordoma of the skull base. This cell line
maintained the expression of brachyury, a chordoma cell marker, at
late passages in culture and generated tumor xenografts closely mimick-
ing the histology and phenotype of parent tumor. In vitro screening
with a library of commercially available kinase inhibitors selected for
specific pathway inhibition and/or cytotoxic activity demonstrated sen-
sitivity of the chordoma cells to rapamycin. Importantly, rapamycin was
also effective in reducing the growth of chordoma tumor xenografts. On
the basis of these results, our patient received rapamycin therapy leading
to a substantial reduction of the tumor growth rate upon follow-up
magnetic resonance (MR) images. This is the first chordoma case in
which chemotherapy was tailored on the basis of the sensitivity of
patient-derived tumor cells to specific small molecule inhibitors.
Materials and Methods
Patient Information and Clinical Material
Tumor tissue was obtained from a 30-year-old female patient with
recurrent chordoma of the skull base. The patient had undergone a first
surgery 3 years before admission with partial tumor resection through a
transoral approach followed by craniocervical fixation. Further surgery
and neoadjuvant treatments were refused by the patient. OnMR image
follow-up, the chordoma showed a slow growth for about 2 years, fol-
lowed by accelerated growth with a tumor doubling time that decreased
from 40.1 to 7.4 months [4] (Figure 1, A and B). Upon admission,
the patient presented with cachexia, respiratory insufficiency, left-sided
paresis, midline and right hemispheric cerebellar syndrome, and palsy
of cranial nerves from V to XII on the right. MR images demonstrated
a huge mass lesion involving the clivus, sphenoid region, right petrous
bone, and temporal fossa with severe brain stem compression. Tra-
cheostomy and gastrostomy were performed. The patient underwent
a two-stage surgery through subtemporal/infratemporal and retro-
sigmoid approaches with extensive tumor resection and decompression
of the temporal lobe and brain stem. Postoperatively, the patient’s
neurologic conditions improved remarkably. Gastrostomy was closed
before discharge and tracheostomy 1 month later.
Tumor tissue was taken for establishment of cell cultures at the
first staged surgical procedure. The patient provided informed consent.
Histologic examination of surgical specimens from both procedures
revealed a typical chordoma with physaliphorous cells embedded in a
mucoid or chondroid matrix (Figure 1C ). The tumor expressed
brachyury (H-210, rabbit polyclonal antibody; Santa Cruz Biotech-
nology Inc, Santa Cruz, CA), epithelial membrane antigen (EMA;
clone E29; Dako, Glostrup, Denmark), vimentin (clone V9; Dako),
cytokeratin (clone AE1 + AE2; Dako), and S-100 (rabbit polyclonal
antibody; Dako). The proliferation rate, as determined by immuno-
staining with anti–Ki-67 antibody (clone MIB-1; Dako), was between
5% and 8%. Phosphatase and tensin homolog (PTEN), studied with a
mouse monoclonal antibody (clone 28H6; Novocastra Ltd, Newcastle,
United Kingdom), was not expressed in approximately 70% of the
tumor cell (Figure 1C).
Cell Cultures
Immediately after surgical removal, chordoma tissue samples were
mechanically dissociated. Cells were cultured in Dulbecco’s modified
Eagle’s medium–F12 (1:1; Gibco, Milan, Italy) supplemented with
10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin (Gibco), in the presence of human recombinant epi-
dermal growth factor (40 ng/ml) and human recombinant basic fibro-
blast growth factor (20 ng/ml; PeproTech, Inc, Rocky Hill, NJ) [8].
Adherent cells were grown to 80% confluence, detached from the
flask with trypsin/EDTA (0.25% trypsin; Gibco), and replated at a
density of 20 × 103/ml in 75-cm2 tissue culture flasks. The cells were
replated every 4 days, corresponding to approximately two population
doublings. For growth curve analysis, cells were plated at a density of
2 × 104/ml in 96-well plates in triplicate. Cell proliferation was moni-
tored by counting the cells and confirmed by using the CellTiter-Blue
viability assay (Promega, Madison, WI).
Immunocytochemical Staining of Cultured Chordoma Cells
For immunostaining, cultured cells were plated onto polylysine-
coated glass coverslips. Cells were then fixed with 4% paraformaldehyde
and stained with the aforementioned antibodies. After methanol and
H2O2 permeabilization, cells were incubated at room temperature for
1 hour with anti-brachyury antibody at 1:50. The primary antibodies
were visualized using the avidin-biotin-peroxidase complex method
(UltraTek HRP Anti-polyvalent; ScyTek, Logan, UT) according to the
instruction manual. 3,3′-Diaminobenzidine was used as the enzyme
substrate to observe the specific antibody localization, and Mayer
hematoxylin was used as a nuclear counterstain.
In Vitro Small Molecule Testing
Cells were plated at a density of 2 × 104/ml in a 96-well plate
in triplicate. Twenty-four hours after seeding, cells were treated
with 80 kinase inhibitors that belong to a commercial chemical li-
brary (Enzo Life Sciences/Biomol, Lausen, Switzerland; http://www.
enzolifesciences.com/BML-2832/kinase-inhibitor-library) at 5 μM
concentration (Table W1). After 48, 72, and 96 hours of treatment,
cell viability was assessed using CellTiter-Glo assay (Promega, Milan,
Italy) following the manufacturer’s instructions. Titration experiments
were performed using serial dilution of the selected compounds.
Western Blot Analysis
Cell pellets were washed twice with cold phosphate-buffered saline
(PBS) and resuspended in a 50 mM Tris-HCl (pH 7.5), 200 mM
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NaCl, and 1% NP-40 ice-cold buffer containing Proteinase Inhibitor
Cocktail (Sigma, St Louis, MO) and incubated for 30 minutes on
ice. After centrifugation at 10,000g for 10 minutes, lysates were col-
lected as supernatants. For each sample, 20 μg of cell extracts were
resolved on a 4% to 12% sodium dodecyl sulfate–polyacrylamide
gel using a mini-gel apparatus (Bio-Rad Laboratories, Richmond,
CA) and transferred to Hybond-C extra nitrocellulose (Amersham
Pharmacia Biotech, Piscataway, NJ). Membrane was blocked for
1 hour with 5% nonfat dry milk in TBS containing 0.05% Tween-
20 and incubated overnight with primary antibody. The following
primary antibodies were used: mouse anti–β-actin (Oncogene Re-
search Products, La Jolla, CA), rabbit anti-brachyury (Santa Cruz
Biotechnology Inc), mouse monoclonal anti-brachyury (5H8; Novus
Biologicals, Littleton, CO), rabbit anti-mTOR, rabbit anti–phospho-
mTOR (Ser2448), rabbit anti-Akt, rabbit anti–phospho-Akt (Ser473),
rabbit anti-tuberin/tuberous sclerosis complex protein 2 (TSC2), rab-
bit anti–phosphor-tuberin/TSC2 (Thr1462), rabbit anti–p70 S6, and
rabbit anti–phospho–p70 S6 kinase (p70 S6K, Thr389; all from Cell
Signaling Technology, Danvers, MA). Washed filters were then incu-
bated for 45 minutes with HRP-conjugated anti-rabbit or anti-mouse
secondary antibodies (Amersham Pharmacia Biotech) and visualized by
using an enhanced chemiluminescence detection system (SuperSignal
West Pico Chemiluminescent Substrate; Pierce, Rockford, IL). The
quantization of phosphorylated protein expression was determined
after it was normalized to corresponding total protein by measuring
the optical density of respective band blots using the Quantity One
software (Bio-Rad Laboratories).
KRAS and BRAF Mutational Analysis
DNA extraction was performed both on macrodissected paraffin
slides, containing 80% tumor cells, and on cultured chordoma cells
(1 × 106) using the QIAamp Tissue Kit (Qiagen, Hilden, Germany)
Figure 1. (A) Follow-up T2-weighted axial MR images showing the skull base chordoma, which appears as an inhomogeneous hyperintense
mass lesion (arrows) involving the right petroclival area, petrous bone, sphenoid region, and middle cranial fossa. Upper panel: MR images
at the level of petroclival junction. Lower panel: MR images at the level of middle cranial fossa. (B) Growth curve of clival chordoma
as assessed on follow-up MR images. (C) Typical histologic appearance of chordoma with large clusters of physaliferous cells that stain
positive for EMA and brachyury, with a strong membranous expression of EGFR. There is loss of PTEN expression. Scale bars, 120 μm.
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following the manufacturer’s protocol. The KRAS gene (exons 2 and 3)
was amplified using the following primers: for exon 2, forward—
5′-GCC TGC TGA AAA TGA CTG AAT-3′ and reverse—5′-TTA
TCT GTA TCA AAG AAT GGT C-3′; for exon 3, forward—
5′-GAC TGT GTT TCT CCC TTC T-3′ and reverse—5′-TGG
CAA ATA CAC AAA GAA AG-3′.
The BRAF gene (exons 11 and 15) was amplified using the follow-
ing primers: for exon 11, forward—5′-TTA TTG ATG CGA ACA
GTG AAT AT-3′ and reverse—5′-TTA CAG TGG GAC AAA
GAA TTG-3′; for exon 15, forward—5′-TCA TAA TGC TTG
CTC TGA TAG GA-3′ and reverse—5′-GGC CAA AAA TTT
AAT CAG TGG A-3′. Briefly, DNA (100–200 ng) was amplified
in a mixture containing 1× polymerase chain reaction (PCR) buffer
[20 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl2], deoxyribonu-
cleoside triphosphates (dNTPs; 200 mM each), primers (20 pM each),
and 0.5 U of GoTaq polymerase (Promega, Milan, Italy) in a final
volume of 25 μl. PCR conditions were given as follows: initial de-
naturation at 95°C for 8 minutes, followed by 35 cycles at 95°C for
40 seconds, 55°C for 40 seconds, and 72°C for 40 seconds. After visu-
alization onto agarose gel, PCR products were treated with ExoSAP-IT
(USB Corp, Cleveland, OH) following the manufacturer’s protocol,
amplified with BigDye Terminator version 3.1 Cycle Sequencing Kit
(Applied Biosystems, Milan, Italy) using forward and reverse primers,
and sequenced with an ABI PRISM 3100-Avant Genetic Analyzer
(Applied Biosystems). Water was used as negative control.
Chordoma Cell Grafting and Rapamycin Treatment of
Immunocompromised Mice
Experiments involving animals were approved by the Ethical Commit-
tee of the Catholic University School of Medicine (Rome, Italy). Nude
athymic and non-obese diabetic–severe combined immunodeficiency
(NOD-SCID) mice (males, 4–6 weeks of age; both from Charles River,
Milan, Italy) were implanted subcutaneously with 1 × 106 chordoma cells
at passage 10 (P10). For grafting, cells were resuspended in 0.1 ml of
cold PBS, the suspension was mixed with an equal volume of cold
Matrigel (BD Biosciences, Bedford, MA), and the mixture was im-
planted onto the right flank by subcutaneous injection using a 25-gauge
needle. Only one injection was performed on a single mouse. Mice
were kept under pathogen-free conditions in positive-pressure cabinets
(Tecniplast Gazzada, Varese, Italy) and observed weekly for the visual
appearance of tumors at injection sites. Tumor diameter was measured
using a caliper, and tumor volume was calculated in mm3 according to
the equation, V = (a2 × b)/2, where a is the shortest diameter and b is
the longest diameter of xenografts. A group of nude athymic mice
harboring chordoma xenografts was treated with rapamycin (20 mg/kg
per day) [19,20]. Rapamycin (0.6 mg in 0.15 ml of saline) was injected
intraperitoneally (i.p.) once daily for 4 weeks (5 days per week; total of
20 injections). Mice were maintained up to 4 weeks without any fur-
ther treatment, except for measurement of tumor mass, then sacrificed
with an overdose of barbiturate. Controls included mice i.p. injected
with an equal volume of saline.
Histology and Immunohistochemistry of Chordoma Xenografts
Mice were deeply anesthetized and transcardially perfused with
0.1 M PBS (pH 7.4), followed by 4% paraformaldehyde in 0.1 M
PBS. The implants were surgically removed and embedded in paraffin.
In paraffinized sections (3-μm thick), a previous step of heat-induced
antigen retrieval technique by microwave oven processing (two cycles
of 5 minutes, 750 W) in citrate buffer was used. After incubation with
the primary antibody, immunodetection was performed using the
avidin-biotin complex peroxidase method (Scytek) using freshly made
DAB as a chromogen. For brachyury immunostaining, antigen re-
trieval was performed in a water bath at 100°C using 1× sodium citrate
for 15 minutes. Endogenous peroxidase activity was blocked with
0.3% H2O2, and sections were incubated at room temperature for
1 hour with anti-brachyury antibody at a dilution of 1:50.
Results
Chordoma Cell Cultures
A chordoma cell line, herein named UCSC-CH1, was established
from a tumor specimen obtained during the first staged surgical pro-
cedure. The chordoma culture was composed of two distinct cell
fractions, fusiform or spindle-like cells and physaliferous cells. At early
passages in vitro (P0–P6), the fusiform cells represented about 75%
to 80% of the cell population with the remaining fraction being com-
posed by physaliferous cells. Over time, the fusiform cells slightly out-
grew the physaliferous cells and consistently accounted for 85% to
90% of the cell population at late passages. Growth curves indicated
that the doubling time of the cell population was approximately 2 days
(Figure W1). Up to P30, brachyury was expressed by virtually all of
the cultured cells as assessed by immunohistochemistry but was stron-
gest in the fusiform cells (Figure 2A). Unlike brachyury expression, the
Figure 2. (A) CulturedUCSC-CH1 chordoma cells at P3 to P30. Expres-
sion of brachyurywasmaintained over passages. Expression of EMA
consistently decreased at passages later than P10. (B) Immunoblot
analysis of brachyury expression in UCSC-CH1 cells at different
passages. Cell lysates of the lung carcinoma cell line A549 were
used as control.
776 Targeted Therapy for Skull Base Chordoma Ricci-Vitiani et al. Neoplasia Vol. 15, No. 7, 2013
expression of EMA by the cultured chordoma cells was less uniform.
At the early passages (P0–P6), EMA was highly expressed in all cells,
while at late passage only 20% to 30% of the physaliferous cells main-
tained EMA expression, whereas the fusiform cells lost expression of
EMA (Figure 2A). Western blot analysis of UCSC-CH1 chordoma
cells confirmed brachyury expression that was maintained to at least
P30 (Figure 2B).
In Vitro Compound Screening
To potentially identify chordoma-targeted small molecule therapies,
we screened a commercially available kinase inhibitor library (Enzo
Life Sciences/Biomol; http://www.enzolifesciences.com/BML-2832/
kinase-inhibitor-library) for antiproliferative activity in the UCSC-
CH1 chordoma cell line and identified two compounds, rapamycin
and damnacanthal, that inhibited chordoma cell growth over a relevant
concentration range with respect to their known target specificity (Fig-
ure 3, A–C). Additional compounds were antiproliferative at an initial
testing concentration of 5 μM but were subsequently determined to
work through nonselective mechanisms based on a more detailed
concentration response test (Table W2 and Figure W2). Such a result
was expected as these kinases belong to the PI3K/Akt and KRAS/
mitogen-activated protein kinase (MAPK) pathways, which have been
identified as important oncogenic pathways; the PI3K/Akt pathway
mediates cell survival and growth, whereas the KRAS/MAPK pathway
signals cell differentiation, proliferation, and antiapoptosis.
To confirm the molecular mechanism responsible for the growth
inhibition of UCSC-CH1 cells by rapamycin, we performed Western
blot analysis of the mTOR pathway. Rapamycin targeting of mTOR
led to a reduction of the phosphorylation state both of its upstream reg-
ulator Akt (Ser473) and of its downstream effector p70 S6K (Thr389;
Figure W3).
Since chordoma has been reported in patients with tuberous sclerosis
and inactivation of TSC1 and TSC2 has been suggested to play a role
in chordoma development [21–24], we evaluated the state of TSC1/2
complex in UCSC-CH1 cells and its possible modulation after rapa-
mycin treatment. In this molecular pathway, Akt negatively regulates
the activity of TSC1/2 complex by TSC2 (tuberin) phosphorylation
(Thr1462). When TSC proteins are inactivated, mTOR is phosphory-
lated, thereby triggering translation, cell growth, and proliferation [24].
As shown by immunoblot with anti–phospho-tuberin/TSC2, TSC2
activity in UCSC-CH1 cells was inhibited by phosphorylation (Fig-
ure W3B). The activity of TSC1/TSC2 complex was not affected by
rapamycin treatment.
Though rapamycin induced substantial growth inhibition and
phospho-extracellular regulated kinase (pERK) reduction (data not
shown), a fraction of chordoma cells was resistant to treatment. To
potentiate rapamycin activity, we treated the UCSC-CH1 cells with
a combination of rapamycin and U-0126, a MAPK pathway inhib-
itor. However, the combination of both compounds did not increase
rapamycin-mediated cytotoxicity (Figure W4).
KRAS and BRAF Mutational Analysis
Given the sensitivity of UCSC-CH1 cells to rapamycin and the
activation of the mTOR signaling pathway, we investigated the up-
stream oncogenes KRAS and BRAF. A heterozygous mutation at codon
12 (G12V) of KRAS was identified in the DNA from both patient’s
chordoma tissue and cultured UCSC-CH1 cells, which were assessed
at P3, P12, and P30 (Figure W5). No mutations were identified in
BRAF, exons 11 and 15.
Chordoma Tumor Xenografts and Effects of
Rapamycin In Vivo
Of five SCID mice that had been grafted with the UCSC-CH1
cells, three developed subcutaneous nodules that reached a mean diam-
eter of 13 to 15 mm after 6 months (Figure 4A). The histologic pattern
of the tumor xenografts strongly resembled that of the parental tumor
with prominent clusters of physaliferous cells arranged in lobules or
clusters embedded in a mucoid matrix (Figure 4B). Some areas of
the xenografts mimicked a chondroid pattern, as demonstrated by
the nuclear expression of brachyury and by the cytoplasmic expression
of EMA (Figure 4B). In particular, the reduction of EMA expression
by chordoma cells, which had been observed over in vitro passages, did
not occur in the tumor xenograft.
By 4 months after grafting, subcutaneous tumors also developed in
7 of 12 nude athymic mice injected with UCSC-CH1 chordoma cells.
Then, four mice received rapamycin (20 mg/kg per day i.p.) and
three control mice were injected i.p. with an equal volume of saline
(0.15 ml). Rapamycin was well tolerated and there was no death during
4 weeks of treatment as well as in the subsequent observational time
(4 weeks). In control animals (saline injected), the tumors progres-
sively increased in volume from 152.8 ± 6.9 mm3 (mean ± SEM) im-
mediately before beginning i.p. injection to 286.3 ± 18.4 mm3 8 weeks
later, while tumors from rapamycin-treated mice trended to reduce
their volume (Figure 4, C and D). By the fourth rapamycin cycle,
treated tumors were significantly smaller than control ones (107.8 ±
10.6 mm3 vs 224.6 ± 8.9 mm3, mean ± SEM, P < .001). Upon dis-
continuation of rapamycin, tumors slowly regrew but remained signifi-
cantly smaller than saline-treated tumors (134.7 ± 7.9 mm3 vs 286.3 ±
18.4 mm3, mean ± SEM, P < .001; Figure 4D). Histologic examina-
tion revealed that in rapamycin-treated tumors the lobules of chordoma
cells were separated by large areas consisting of dense and acellular
fibrous tissue (Figure 4E ). The proliferation index, as assessed by
Ki-67 immunostaining, was significantly lower in rapamycin-treated
tumors as compared with control tumors (5.37 ± 0.38 vs 3.07 ± 0.18,
mean ± SEM, P < .005).
Patient Treatment with Rapamycin
Patient treatment started 1 month after the latest surgical procedure.
The treatment schedule was approved by the Ethical Committee of
Università Cattolica del Sacro Cuore (Rome, Italy; P/164/CE/2012).
Before enrollment, the patient underwent a complete clinical eval-
uation, including general physical and neurologic examination, com-
plete blood cell count, serum chemistry [serum creatinine, blood urea
nitrogen (BUN), bilirubin, aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase, γ-glutamyltransferase, electrolytes,
glucose, cholesterol, and triglycerides], urine chemistry, cardiologic
assessment, and chest roentgenogram. Sirolimus (Rapamune; Wyeth
Pharmaceuticals, Havant, United Kingdom) was started at a once daily
dose of 2 mg/day, taken at the same time of day either with low-fat food
or without food. Dose adjustment was based on serum drug level, de-
termined weekly for the first month and then biweekly, to maintain
drug levels within a therapeutic range of 15 to 20 ng/ml [25]. Drugs
interfering with cytochrome CYP3A4 were forbidden, including grape-
fruit juice, and treatment was planned to be discontinued in case of
unacceptable toxicity. The latter was defined as the occurrence of
a hematologic grade ≥3 adverse event or a nonhematologic grade
≥2 adverse event (classified according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 4.0) that
did not recover after treatment interruption. General physical and
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Figure 3. (A) Cell death induction by kinase Biomol inhibitors on UCSC-CH1 tested at early (P3) and late (P16) passages. Data are means ±
SD of three independent experiments. (B) List of inhibitors able to reduce UCSC-CH1 cell viability by 50% or more at 96 hours of treatment,
compared to DMSO-treated control wells. (C) Titration curve of rapamycin in UCSC-CH1 at P3.
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neurologic examination, complete blood cell count, and serum and
urine chemistries were performed every 2 weeks. Rapamycin efficacy
evaluation was based on follow-up brain MR scans. Assessment of tu-
mor volume was performed on T2-weighted axial MR images that were
retrieved from or imported into a dedicated software (Carestream
Health Italia, Genova, Italy). There were no adverse events during
the 9 months of rapamycin treatment and neurologic conditions re-
mained stable. At the 10-month follow-up MR exam, which included
9 months of rapamycin administration, the residual chordoma showed
a moderate increase in size compared to the MR exam performed
1 month after surgery with the tumor volume increasing from 59.3 to
137.5 cm3 (Figure 5, A and B). However, the tumor growth rate over
Figure 4. (A) Chordoma tumor xenografts developed 6 months after subcutaneous grafting of 1 × 106 UCSC-CH1 cells in SCID mice.
(B) Histologic examination of chordoma xenografts showing lobules of physaliferous cells that express both brachyury and EMA. Scale
bars, 160 μm. (C) Chordoma tumor xenografts in control (saline-injected) and rapamycin-treated athymic mice. (D) Growth curves of
chordoma xenografts in control and rapamycin-treated mice. Rapamycin was administered between week 0 and week 4 and then dis-
continued. **P < .001. (E) Histologic examination of control and rapamycin-treated chordoma xenografts. Control tumors showed the
typical histologic pattern of chordoma. In rapamycin-treated xenografts, the lobules of chordoma cells were separated by large areas
of amorphous tissue (asterisk). The chordoma phenotype was maintained in both groups of xenografts. Scale bars, 50 μm in hemato-
xylin and eosin (H&E), brachyury, and EMA and 25 μm in Ki-67.
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the 10-month postoperative interval was 7.8 cm3/month, that is, about
6.1-fold slower than before rapamycin therapy (47.5 cm3/month).
Discussion
The present study is unique because of the following aspects: 1) a cell
line from a chordoma of the skull base has been established; 2) a
targeted agent, rapamycin, has been identified that affects chordoma
cell growth; 3) the efficacy of rapamycin was confirmed on an in vivo
model; and 4) rapamycin therapy was effective in inhibiting the
growth of the patient’s chordoma.
In recent years, several research groups have actively been involved
in establishing chordoma cell lines for preclinical research into devel-
oping effective therapies [8,10–14,16]. To date, a few cell lines have
been obtained from sacral and extra-axial chordomas [10–14,16].
Chordoma of the skull base generated three long-term cell cultures
in our laboratory and one primary tumor xenograft model [8,9]. In
the present study, we describe establishing a cell line from a chor-
doma of the skull base. This cell line maintained brachyury expression
at late passages in vitro and generated tumor xenografts in immuno-
compromised mice that closely mimicked the histology and phenotype
of the parental tumor. Interestingly, the expression of EMA by chor-
doma cells, which decreased with increasing passage in vitro, was
maintained in vivo, suggesting that tumor microenvironment factors
influence the phenotype of chordoma cells. Using an early passage
chordoma line, we performed a small molecule drug screen with a
library of compounds specifically chosen for pathway inhibition and/
or cytotoxic activity and designed to identify, in a short time, one or
more chemotherapeutic agents that may inhibit the extremely fast-
growing chordoma of our patient.
Figure 5. (A) Axial T2-weighted MR images of patient’s chordoma before surgery (upper panel), 1 month after surgery before rapamycin
administration (middle panel), and after 5 months of rapamycin therapy (lower panel). (B) Growth curve of patient’s chordoma over
31 months before surgery (purple line) and 10 months after surgery including 9 months of rapamycin therapy (blue line).
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Tumor xenografts generated by injection of human chordoma cells
in immunosuppressed mice require several months for their growth,
representing a potential issue for translational protocols, particularly
for fast-growing tumors such as the chordoma of our patient. For
example, the primary human chordoma xenograft model described
by Siu et al. required 5 months to grow to a size suitable for drug
assessment [9]. It is important to note that the patient from whom
the chordoma samples were obtained presented with tumor recurrence
only 6 months after surgery [9]. Our chordoma line required 4 months
to develop sizeable subcutaneous nodules and an additional 8 weeks
to assess the efficacy of rapamycin in vivo. As previously noted [8], it
is likely that chordomas generating cell lines or primary xenografts are
extremely aggressive and their growth rate in the patient may be not
compatible with long-lasting preclinical investigations.
Results from the small molecule screen showed that the patient-
derived chordoma cells were sensitive to rapamycin, suggesting a role
for the mTOR signaling pathway in chordoma growth. Han et al.
have recently demonstrated that mTOR complex 1 signaling is abnor-
mally hyperactivated in sporadic chordomas of the sacrum and that
this abnormality is correlated with constitutively activated Akt likely
through loss of PTEN expression [17]. These authors also reported
that rapamycin at 1 nM was effective in repressing the proliferation
of cultured chordoma cells [17]. Furthermore, rapamycin either alone
or in combination with a PI3K inhibitor has been shown to inhibit
chordoma growth in patients and to induce apoptosis in cultured
sacral chordoma cells [25,26].
Our chordoma line displayed significant sensitivity to rapamycin with
a significant decrease in cell number even at a concentration as low
as 0.001 nM. Consistent with previous observations [17], immuno-
histochemical analysis demonstrated loss of PTEN expression in the
chordoma cells. The mTOR pathway is frequently and constitutively
activated in many types of human cancer mainly through activation of
PI3K/AKT and/or inactivation of PTEN. The PI3K/AKT signaling
is activated through a variety of mechanisms including mutation or
amplification of cell surface receptor tyrosine kinases such as epidermal
growth factor receptor (EGFR) and insulin-like growth factor receptor
(IGFR), gain-of-function mutation in the PIK3CA, which encodes the
p110a catalytic subunit of PI3K, and loss of expression of the tumor
suppressor PTEN, which encodes a lipid and protein phosphatase. In
addition to the loss of PTEN, we found mutation of KRAS as a novel
mechanism contributing to chordoma tumorigenesis. This mutation
appears to be rare in chordomas, given that Shalaby et al. did not identify
mutations of KRAS in 61 tumors, including sacrococcygeal, skull-based,
and mobile spine chordomas [27]. Resistance of our cell line to EGFR
antagonists, as assessed by our in vitro compound screening, is consis-
tent with the concept that activating mutations in genes downstream
of EGFR, like KRAS, represent exclusion criteria for treatment with
anti-EGFR agents [28,29] and that alterations in the PI3K pathway,
like PIK3CA gene mutations and loss of PTEN protein expression,
may represent additional negative genetic regulators of EGFR-targeted
therapies [30].
We are aware that a definitive demonstration of rapamycin efficacy
in our patient would imply knowing, as a baseline value, the tumor
growth rate after surgical resection. We attempted to determine the
postoperative growth rate of chordoma tumors in cases similar to our
patient by reviewing pertinent literature. Crockard et al. noted that
surgically resected chordomas of the skull base show a wide distribution
in the their postoperative growth rate, which was assessed as tumor
doubling time on follow-up MR imaging [31]. However, cases with
tumor doubling time as short as 7 months, like our patient, are
expected to require additional surgery within 9 months due to clinical
worsening. Although longer follow-up is warranted, over the 10-month
postoperative interval, that included 9 months of rapamycin treatment,
our patient did well and her neurologic improvement remained stable.
In spite of the potential advances that our approach offers for the
treatment of chordoma, specifically allowing the tailoring of each
protocol based on patient-derived tumor cells, some issues remain.
The first concerns the loss of EMA expression by chordoma cells at
passages later than P10. This phenotypic change may raise the question
of the reliability of chordoma in vitro models. However, results of the
small molecule screen performed in cells between P3 and P16 show that
the loss of EMA expression does not alter sensitivity to rapamycin by
cultured chordoma cells. The second issue concerns the extremely
chemoresistant nature of chordoma that emerges from our in vitro
screening. Therefore, difficulties encountered with chemotherapy for
chordomas do not merely depend on the paucity of in vitro models
but also on the intrinsic chemoresistance of this neoplasm. The third
issue relates with the scarce availability for clinical research of those
compounds that are the pharmaceutically active substances in herbal
drugs. For example, damnacanthal, an anthraquinone compound
isolated from the roots of Morinda citrifolia (Noni), has revealed to
be highly effective in inhibiting the growth of our chordoma cell line
in vitro. This drug has been used for traditional therapy in several
chronic diseases including cancer as galenic product; however, its phar-
maceutical principle is not available for treating patients. Finally, our
conclusions are currently based on a small number of treated animals
and on one single patient. Therefore, larger patient series as well as
additional analyses, like Ki-67 staining of tumor samples from treated
patients, are warranted to validate the efficacy of rapamycin in selected
cases of chordoma.
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Table W1. List of the Library Inhibitors and Their Targets.
Well Pathway Treatment
B01 MEK PD-98059
B02 MEK U-0126
B03 p38 MAPK SB-203580
B04 PKA, PKG, MLCK, and PKC H-7
B05 PKA, PKG, MLCK, and PKC H-9
B06 Pan-specific Staurosporine
B07 EGFRK, PDGFRK AG-494
B08 HER1-2 AG-825
B09 EGFRK Lavendustin A
B10 EGFRK RG-14620
B11 EGFRK Tyrphostin 23
B12 EGFRK Tyrphostin 25
C01 EGFRK, PDGFRK Tyrphostin 46
C02 EGFRK Tyrphostin 47
C03 EGFRK Tyrphostin 51
C04 Negative control for tyrosine
kinase inhibitors
Tyrphostin 1
C05 Tyrosine kinases Tyrphostin AG 1288
C06 EGFRK Tyrphostin AG 1478
C07 Tyrosine kinases Tyrphostin AG 1295
C08 PDGFRK Tyrphostin 9
C09 IRK Hydroxy-2-naphthalenylmethylphosphonic acid
C10 p56 lck Damnacanthal
C11 Syk Piceatannol
C12 Src family PP1
D01 JAK-2 AG-490
D02 IRAK AG-126
D03 PDGFRK AG-370
D04 NGFRK AG-879
D05 PI3K LY 294002
D06 PI3K Wortmannin
D07 PKC GF 109203X
D08 PKC Hypericin
D09 PKC Ro 31-8220
D10 PKC Sphingosine
D11 PKA H-89
D12 PKA, PKG H-8
E01 PKA, PKG HA-1004
E02 PKA, PKG HA-1077
E03 EGFRK, CaMK II 2-Hydroxy-5-(2,5-dihydroxybenzylamino)benzoic acid
E04 CaMK II KN-62
E05 CaMK II KN-93
E06 MLCK ML-7
E07 MLCK ML-9
E08 p58 PITSLRE β1 2-Aminopurine
Table W1. (continued )
Well Pathway Treatment
E09 CDK N9-isopropyl-olomoucine
E10 CDK Olomoucine
E11 Negative control for olomoucine iso-olomoucine
E12 CDK Roscovitine
F01 ERK2, adenosine kinase,
CK1, CK2,
5-Iodotubercidin
F02 BTK LFM-A13
F03 p38 MAPK SB-202190
F04 Src family PP2
F05 CRAF ZM 336372
F06 Flk1 SU 4312
F07 PDGFRK AG-1296
F08 CRAF GW 5074
F09 PKC Palmitoyl-DL-carnitine Cl
F10 PKCδ Rottlerin
F11 Tyrosine kinases Genistein
F12 Negative control for genistein Daidzein
G01 EGFRK Erbstatin analog
G02 PI3K Quercetin dihydrate
G03 Flk1 SU1498
G04 JAK-3 ZM 449829
G05 IKK pathway BAY 11-7082
G06 CK II 5,6-Dichloro-1-B-D-ribofuranosylbenzimidazole
G07 PKCα, PKCγ 2,2′,3,3′,4,4′-Hexahydroxy-1,1′-biphenyl-6,6′-
dimethanol dimethyl ether
G08 JNK SP 600125
G09 GSK-3β, CDK5 Indirubin
G10 GSK-3β Indirubin-3′-monoxime
G11 ROCK Y-27632
G12 GSK-3β Kenpaullone
H01 BTK Terreic acid
H02 Akt signaling pathway Triciribine
H03 Akt BML-257
H04 IKK2 SC-514
H05 Cdk5/p25 BML-259
H06 CK-II Apigenin
H07 EGFRK BML-265 (erlotinib analog)
H08 mTOR Rapamycin
BTK indicates Bruton agammaglobulinemia tyrosine kinase; CaMK II, calmodulin-dependent pro-
tein kinase II; EGFRK, epidermal growth factor receptor kinase; HER1-2, human epidermal growth
factor receptor 1-2; IKK2, inhibitor of nuclear factor kappa-B kinase 2; IRAK, interleukin receptor-
associated kinase; IRK, insulin receptor kinase; JAK-2, Janus kinase 2; MEK, mitogen-activated
protein kinase kinase; MLCK, myosin light chain kinase; NGFRK, nerve growth factor receptor
kinase; PDGFRK, platelet-derived growth factor receptor-associated tyrosine kinase; PKA, cAMP-
dependent protein kinase; PKC, protein kinase C; PKG, cGMP-dependent protein kinase.
Figure W1. Growth curve of UCSC-CH1 at P4. Data are means ± SD
of three independent experiments.
Table W2. IC50 Values of Compounds Active against UCSC-CH1 Chordoma Cell Line.
Treatment IC50
Quercetin dihydrate 5.948562953
BML-265 4.43136049
PP1 4.377361764
LY249002 3.606772465
Triciribine 3.339349257
Erbastin analog 2.906892452
Terreic acid 2.793404793
Tyrphostin 9 2.588057899
Sphingosine 2.538831986
5-Iodotubericin 2.260229722
BAY 11-7082 2.112517096
Rottlerin 2.016850515
Damnacanthal 0.03
Rapamycin 0.007031962
IC50 indicates 50% inhibitory concentration.
Figure W2. Titration curves of the 15 selected compounds at 48, 72, and 96 hours after treatment. Staurosporine was used as control.
FigureW3. Effectof rapamycin treatment (5nM;48,72, and96hours)
on phospho-mTOR and phospho-Akt (A) and on phospho-TSC2 and
phospho–p70 S6K (B). Numbers indicate the ratio of the phosphory-
lated protein normalized to the amount of corresponding total protein.
Figure W4. MAPK pathway inhibition does not increase rapamycin-
mediated cytotoxicity. Effect of rapamycin (Rapa; 5 nM), U-0126 (50,
100, 200 nM) or the combination of both compounds on cell viability
after 24, 48, 72, and 96 hours of treatment. Error bars indicate SD.
Figure W5. The figure shows a fragment of the KRAS sequence
(fromnucleotide 22 to nucleotide 44) frompatient’s chordoma tissue
(A) and UCSC-CH1 chordoma cells at P12 (B). Both samples show
a heterozygous mutation of codon 12 (bar line) with a change of
GGT to GTT. This mutation determines the substitution of a glycine
with a valine amino acid (G12V).
